KZR

Kezar Life Sciences, Inc.

0.84 USD

Last updated Dec 4, 20:21 UTC

Yesterday HIGH

$0.86

Yesterday LOW

$0.82

52w HIGH

$7.89

52w LOW

$0.67

EPS

-0.32

PE

-2.62

Next Earnings

Mar 12, 2024

Overview News Insider Transactions Government Trades

Kezar Life Sciences, Inc. stock is down -0.06% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November. 67% of analysts rate it a buy.

Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

kezarlifesciences.com

Benzinga Insights

Tue Aug 22, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Lisa Levin

Mon Aug 21, 2023

Top 5 Health Care Stocks That Could Blast Off This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Benzinga Insights

Tue Aug 15, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights

Fri Aug 11, 2023

Stocks That Hit 52-Week Lows On Friday

During the Friday's sesion, 157 stocks hit new 52-week lows.
Lisa Levin

Fri Aug 11, 2023

Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.
Benzinga Insights

Fri Aug 11, 2023

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights

Fri Aug 11, 2023

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
richadhand@benzinga.com

Fri Aug 11, 2023

Wells Fargo Downgrades Kezar Life Sciences to Equal-Weight

Wells Fargo analyst Derek Archila downgrades Kezar Life Sciences (NASDAQ:KZR) from Overweight to Equal-Weight.
richadhand@benzinga.com

Fri Aug 11, 2023

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Lowers Price Target to $18

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and lowers the price target from $19 to $18.
Benzinga Newsdesk

Thu Aug 10, 2023

Kezar Life Sciences Q2 EPS $(0.34) Down From $(0.25) YoY

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.34) per share. This is a 36 percent decrease over losses of $(0.25) per share from the same period last year.